文献速递前列腺癌

177Lu-PSMA-I&T治疗转移性去势抵抗性前列腺癌的疗效、毒性及预测因素

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2018-11-22

本研究回顾性分析了100例接受177Lu-PSMA-I&T放射配体治疗的mCRPC患者,共319个周期。结果显示38例患者PSA下降≥50%,中位临床无进展生存期4.1个月,中位总生存期12.9个月。内脏转移和LDH升高与较差疗效相关,3/4级血液学毒性较低。

要点

  • 177Lu-PSMA-I&T在晚期mCRPC中显示良好活性,超过三分之一患者PSA下降≥50%。
  • 内脏转移和LDH升高与较差的PSA反应及更短生存相关。
  • 治疗12周内PSA下降≥50%的患者cPFS和OS更长。

核心结论

  • 177Lu-PSMA-I&T在晚期mCRPC患者中显示良好活性且毒性较低。
  • 内脏转移和LDH升高与更差的治疗结局相关。

研究设计与样本

  • 回顾性分析100例接受177Lu-PSMA-I&T治疗的mCRPC患者,共319个周期(中位2周期,范围1-6)。
  • 治疗方案为每6-8周给予7.4 GBq,最多6周期。

主要发现

  • 38例患者实现PSA下降≥50%,中位cPFS为4.1个月,中位OS为12.9个月。
  • 35例患者有内脏转移,与较差的PSA反应及更短的cPFS和OS相关。
  • LDH升高与更短的cPFS和OS相关。
  • 治疗12周内PSA下降≥50%的患者cPFS和OS更长。

关键数值与推荐

  • 入组条件包括既往接受阿比特龙或恩扎卢胺、既往紫杉类化疗或化疗不合格、PET扫描PSMA配体摄取阳性。
  • 3/4级血液学毒性:贫血9%,血小板减少4%,中性粒细胞减少6%。
  • 未观察到3/4级非血液学毒性。

临床怎么用

  • 对于既往多线治疗后的mCRPC患者,177Lu-PSMA-I&T可作为治疗选择之一。
  • 治疗前应评估内脏转移和LDH水平以预测疗效。
  • 治疗早期PSA下降≥50%提示更好的生存获益。

局限性

  • 回顾性研究设计。
  • 样本量有限(100例)。
  • 同情用药方案可能影响结果普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly being used in metastatic castration-resistant prostate cancer (mCRPC). The objective of this study is to report our clinical experience with RLT using 177-lutetium-labeled PSMA-I&T. A total of 100 patients were treated under a compassionate use protocol with a total number of 319 cycles (median two cycles, range 1-6). Eligibility criteria included previous treatment with abiraterone or enzalutamide, previous taxane-based chemotherapy or chemoineligibility, and positive PSMA-ligand uptake at positron-emission tomography scan. The 177Lu-PSMA-I&T was given 6-8 weekly with an activity of 7.4 GBq up to six cycles. The median number of previous mCRPC regimens was 3 (range 1-6), and 35 patients had visceral metastases. Prostate-specific antigen decline of ≥50% was achieved in 38 patients, median clinical progression-free survival (cPFS) was 4.1mo, and median overall survival (OS) was 12.9mo. Subgroup analyses identified an association of visceral metastases with a poor prostate-specific antigen (PSA) response and shorter cPFS and OS, and an association of rising lactate dehydrogenase (LDH) with shorter cPFS and OS. Patients achieving PSA decline of ≥50% within 12wk of treatment showed longer cPFS and OS. Treatment-emergent hematologic grade 3/4 toxicities were anemia (9%), thrombocytopenia (4%), and neutropenia (6%). Grade 3/4 nonhematologic toxicities were not observed. RLT with 177Lu-PSMA-I&T showed good activity in more than one-third of patients with late-stage mCRPC at low toxicity. Presence of visceral metastases and rising LDH were associated with worse treatment outcome. PATIENT SUMMARY: We analyzed the treatment outcome and toxicity of prostate-specific membrane antigen-targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer. We found that a good treatment response could be achieved in a subgroup of patients with few side effects. We also observed that treatment outcome was worse in patients with organ metastases and elevated lactate dehydrogenase in blood tests.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Heck MM, Tauber R, Schwaiger S, et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018. PMID: 30473431. doi:10.1016/j.eururo.2018.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。